VPH2

Heart failure accounts for almost a quarter of all admissions to hospital for cardiovascular events, has a high mortality (median survival around 18 months), and places a great burden on all healthcare systems, with estimated direct costs of £905m (1350m) in the United Kingdom in 2000, 2% of total NHS expenditure.

Virtual pathological heart of the virtual physiological human (VPH2) project aims to develop a patient-specific computational modelling and simulation of the human heart to assist the cardiologist and the cardiac surgeon in defining the severity and extent of disease in patients with post-ischemic Left Ventricular Dysfunction (LVD), with or without ischemic mitral regurgitation (IMR). Specific computational methods will allow clinical decision making and planning of the optimal treatment for left ventricle-valve repair. The goal is not only to deploy a fully validated technology to partner clinical institutions, but also to develop a sustainable business model associated to it.

The associated technological aim of the project is to deliver the most advanced software application framework for the development of computer-aided medicine in cardiology and cardiac surgery available in the world, going beyond the state of the art of available models.

This goal will be achieved by integrating some of the leading Open Source software in the area of computer-aided medicine and of computational bioengineering. This framework will be used by VPH2 to realise its objectives, but also by any other future project (academic or industrial) aiming to improve or extend VPH2 objectives.

For further information, please visit:
http://www.vph2.eu

Project co-ordinator:
GMD - Gesellschaft für Medizinische Datenverarbeitung mbH

Partners:

  • Intercon Sp. Z o.o. (Poland)
  • Euro PMS ltd (United Kingdom)
  • Sorin Biomedica Cardio S.r.l. (Italy)
  • SCS S.r.l. (Italy)
  • EREYNITIKO AKADIMAIKO INSTITOUTO TECHNOLOGIAS YPOLOGISTON (Greece)
  • Westfälische Wilhelms-Universität Münster (Germany)
  • PATMOS S.r.l. (Italy)
  • Aminio AB (Sweden)
  • Ecole Polytechnique Fédérale de Lausanne (Switzerland)
  • University of Bedfordshire (United Kingdom)
  • Regione Lombardia (Italy)
  • Quality & Reliability S.A (Greece)

Timetable: from 07/2008 - to 06/2011

Total cost: € 5.180.000

EC funding: € 3.780.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

MRI Predict Intelligence Levels in Child…

A group of researchers from the Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) took 4th place in the international MRI-based adolescent intelligence prediction competition. For the first...

CAD4TB: Artificial Iintelligence for Tub…

Is it possible to screen thousands of people for tuberculosis using artificial intelligence in a country where internet barely exists? It is with CAD4TB. As of October, this innovative software...

Pros and Cons of Mommy Mobile Apps

Mobile phone apps are increasingly being used to support breastfeeding decisions - sometimes at a cost, a Flinders University study indicates. The objective approach of most infant feeding (IF) apps...

Finally, Machine Learning Interprets Gen…

In this age of "big data," artificial intelligence (AI) has become a valuable ally for scientists. Machine learning algorithms, for instance, are helping biologists make sense of the dizzying number...

Philips Expands its Range of Consumer-Fo…

At CES 2020, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its expansion of personalized consumer health solutions that help shape the industry of...

Gloucestershire Hospitals Announce Signi…

Gloucestershire Hospitals NHS Foundation Trust has gone live with the first elements of its Allscripts Sunrise electronic patient record just five months after signing a contract with the company. The trust...

Bayer and Exscientia Collaborate to Leve…

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary...

A Better Testing Method for Patients wit…

Parkinson's disease is a neurodegenerative disorder that manifests through symptoms such as tremor, slow movements, limb rigidity and gait and balance problems. As such, nearly all diagnostic testing revolves around...

Artificial Intelligence (AI) can Detect …

A new technology for detecting low glucose levels via ECG using a non-invasive wearable sensor, which with the latest Artificial Intelligence can detect hypoglycaemic events from raw ECG signals has...